819 Capital Partners has recently invested in Vidiia Ltd. from 819 Evergreen Fund, alongside a bio-scientist entrepreneur, the University of Surrey and Brunel University London.
Accelerating the growth strategy
Vidiia commercialises a fast and accurate molecular diagnostic testing platform with built-in Artificial Intelligence (AI). The new funding will be used to accelerate the company’s growth strategy.
David Rimer, CEO and Founder of Vidiia: “With the funds we can implement our growth strategy, which aims to commercialise existing assays ready for market, develop new assays with universities and enhance our AI powered testing platform. Vidiia’s Assay Accelerator service, pulls tests off university benches and gets them to market, which we have now proven several times.”
Strong testing platform
Vidiia has a strong testing platform, which is explained by Dr Nick Hutchings, one of the investors in this round: “Assays are reproducible tools that allow us to understand medicine and biology at a molecular level. I am excited to join Vidiia and help scientists to develop and commercialise new assays on the world class Vidiia platform.”
Sven Kempers, director at 819 Capital Partners, expresses trust in Vidiia’s platform and team: “Vidiia’s technology provides many testing options for rapid diagnoses. We are confident that the team will successfully execute the growth strategy.”
Academic validation
Vidiia has strong support from academic institutions, such as Brunel University London and University of Surrey.
Dr Averil Horton – Head of Business Development and Innovation, Brunel University London – explains: “The Vidiia Assay Development Programme has enabled Brunel to place innovative bio-science IP within a structured framework to commercialisation. Their methodology and AI powered testing platform mean they have the end-to-end knowledge and tools for success.”
Professor Lisa Collins – Pro-Vice-Chancellor, Research and Innovation at the University of Surrey – said: “It is fantastic to see the groundbreaking research of our scientists being brought to market with the help of Vidiia. It is important that the scientific community and industry partners continue to work together to develop innovative testing products to identify infectious diseases.”
Professor Roberto La Ragione – Professor of Veterinary Microbiology and Pathology, School of Veterinary Medicine, and Head of the School of Biosciences at the University of Surrey – said: “Infectious diseases remain a global threat to human and animal health, and our economies. Funding is necessary to enable Vidiia and our scientists to continue our work in developing highly accurate and rapid tests to prevent the next pandemic.”
Hands-on experience
David Rimer, concludes that investment brings more than just the funding: “We are delighted to be working with 819 and Dr Nick Hutchings. Both parties bring the crucial hands-on experience and connections that Vidiia were looking for. The continued support from our university partners also provides a significant boost beyond financial investment.”
819 Capital Partners invested in Vidiia Ltd. from 819 Evergreen Fund.
More information about Vidiia Ltd. on: https://vidiia.com/
